卡那单抗在治疗选择有限的患者的难治性痛风性疾病中的应用：希腊沃拉阿斯克利皮翁综合医院风湿病诊所的经验。
The use of Canakinumab in treating resistant gouty disease in patients with limited therapeutic options: The experience of the Rheumatology Clinic of Asklipeion General Hospital of Voula, Greece.
作者信息
Theotikos Evangelos, Raftakis Ioannis, Elezoglou Antonia, Antoniadis Christodoulos
机构信息
Asklipeion General Hospital of Voula, Athens, Greece.
出版信息
Mediterr J Rheumatol. 2017 Mar 28;28(1):48-51. doi: 10.31138/mjr.28.1.48. eCollection 2017 Mar.
Abstract
Gout is an autoinflammatory disease caused by monosodium urate mono hydrate crystal deposition in tissues or the supersaturation of extracellular fluids of uric acid. In this study, we are going to report the experience of the Asklepeion Voula Rheumatology Clinic, treating four patients with gouty arthritis who received Canakinumab.
摘要
痛风是一种自身炎症性疾病，由单水尿酸钠晶体在组织中沉积或细胞外液尿酸过饱和所致。在本研究中，我们将报告阿斯克勒庇俄斯·武拉风湿病诊所治疗4例接受卡那单抗治疗的痛风性关节炎患者的经验。
Zotero 插件